Ask AI
Back Back
Tx Selection and Optimization in MCL

CME

Optimizing Mantle Cell Lymphoma Care: Case-Based Guidance From EU Experts

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: May 29, 2026

Expiration: November 28, 2026

Mats Jerkeman
Mats Jerkeman, MD, PhD
CME/CE Information

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Mats Jerkeman, MD, PhD, provides a European perspective on the current treatment algorithm, guidelines, and evidence-based approaches for the optimal integration of available treatments into the management of patients with mantle cell lymphoma (MCL) with careful consideration of patients’ age, fitness level, presence of high-risk features, preexisting comorbidities, and concomitant medications.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Decera Clinical Education plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after completing the activity. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with MCL do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

A 73-year-old man presents with lymphadenopathy and left upper quadrant pain. Lymph node biopsy shows TP53 mutation–positive MCL, with diffuse variant disease and Ki-67 of 40%. Staging revealed diffuse enlarged lymph nodes, bone marrow, and enlarged spleen (stage IVa). Preexisting comorbidities include hypertension and atrial fibrillation. In your current practice, what would you recommend as the optimal first-line treatment for this 73-year-old man?

A 72-year-old man was diagnosed with MCL 5 years ago. At initial diagnosis, staging revealed stage IV disease with largest lymph node measuring 3 cm, and biopsy showed a Ki-67 score of >30%. His disease has a pleomorphic histology, and the TP53 mutation status was not assessed. As first-line therapy, he received the Nordic regimen followed by ASCT with carmustine/etoposide/cytarabine/melphalan (BEAM) and maintenance rituximab for 3 years. Now, at age 72, he experienced disease progression; imaging reveals disease above and below the diaphragm. At this time, which treatment would you initiate for this patient?

A 75-year-old man recently initiated acalabrutinib after experiencing disease progression on immunochemotherapy induction followed by 3 years of rituximab maintenance therapy. Seven days after the initiation of acalabrutinib, he starts complaining of severe headaches. Which of the following approaches would you educate this patient to avoid in the management of headaches that he is experiencing after initiating treatment with acalabrutinib?

BACK | NEXT